



**THE FOUNDATION
FOR SECURE
MARKETS®**

#55131

Date: September 03, 2024

Subject: Taro Pharmaceutical Industries Ltd. - Cash Settlement/Acceleration of Expirations
Option Symbol: TARO
Date: 06/24/2024

On May 22, 2024, Shareholders of Taro Pharmaceutical Industries Ltd. (TARO) voted concerning the proposed merger with a wholly owned subsidiary of Sun Pharmaceutical Industries Limited, a wholly owned subsidiary of Alkaloida Chemical Company ZRT. The merger was approved and subsequently consummated before the open on June 24, 2024. **As a result, each existing TARO Ordinary Share will be converted into the right to receive \$43.00 net cash per share.**

NOTE: Taro Pharmaceutical Industries Ltd. received an Israeli Tax Authority ruling, exempting non-Israeli shareholders from withholding, provided that the shareholder provides the designated agent with the appropriate tax declaration regarding residency and satisfies other conditions as stated in the TARO Proxy Statement dated April 15, 2024 ("Proxy"). Investors are referred to the Proxy for a complete discussion of relevant tax considerations. As a result, the TARO options deliverable will not be reduced by withholding.

Contract Adjustment

Date: June 24, 2024

**New Deliverable
Per Contract:** \$4,300.00 Cash (\$43.00 x 100)

TARO options, which were delayed from June 24, 2024 through August 30, 2024, are no longer subject to delayed settlement, effective September 3, 2024.

Settlement in TARO options will take place through OCC's cash settlement system. Settlement will be accomplished by payment of the difference between the extended strike amount and the cash deliverable.

Acceleration of Expirations

Pursuant to OCC Rule 807, equity stock option contracts whose deliverables are adjusted to call for cash only delivery will be subject to an acceleration of the expiration dates for outstanding option series. (See OCC Information Memo 23707) Additionally, the exercise by exception (ex by ex) threshold for expiring series will be \$.01 in all account types.

All series of Taro Pharmaceutical Industries Ltd. options whose expiration dates are after 09-20-2024 will have their expiration dates advanced to 09-20-2024. Expiration dates occurring before 09-20-2024 (e.g.,

Flex options) will remain unchanged.

All Taro Pharmaceutical Industries Ltd. options will utilize a \$.01 exercise threshold.

Option Symbol: TARO

Existing Expiration: All months

New expiration date: 09-20-2024

Existing American-style Taro Pharmaceutical Industries Ltd. options remain exercisable at the option of the holder prior to their expiration. Exercised options will continue to settle in two business days.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.